Infinity Pharmaceuticals (NASDAQ: INFI) novel approach is based on Targeting Immune Suppressive Macrophages by selectively inhibiting PI3K-Gamma. The Company’s lead candidate eganelisib, is a first-in-class, oral, once-daily selective inhibitor of phosphoinositide-3-kinase gamma (PI3K-gamma), that has the potential to transform the immuno-oncology space. IPI-549 has demonstrated...
Lexicon Pharmaceuticals (NASDAQ: LXRX), a biopharmaceutical company leveraging its proprietary Genome5000™ program to develop therapeutics for the treatment of disease such as diabetes, metabolism, oncology and neuropathic pain, announced that the Food and Drug Administration (FDA) has reiterated its rejection of the Company’s New Drug...
Epilepsy also known as “seizure disorder” is the fourth most common neurological disorder. This chronic condition affects 65 million people worldwide. The U.S has 3.4 million people living with this condition, with 1 in 26 people developing epilepsy over their lifetime. 150,000 new cases are...
